Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH

Boehringer Ingelheim and Pharmaxis yesterday announced they have started a Phase IIa trial assessing BI 1467335 in NASH. The drug is an oral inhibitor which works by blocking leukocyte adhesion and tissue infiltration in inflammatory processes underlying the disease. NAFLD (Non-Alcoholic Fatty Liver Disease), and its more serious form NASH, is prevalent amongst patients with type 2 Diabetes. NASH is the main cause of liver fibrosis and cirrhosis and no efficient treatments are currently available for it. The trial initiated by the two companies is multi-center and double-blind and will enroll 150 patients with clinical evidence of NASH. The enrolled patients will be randomized to receive either one of four BI1467335 doses or placebo for a 12-week treatment period. (Source Boehringer Ingelheim)